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Background/Aims: Cytomegalovirus (CMV) reactivations are 
frequently observed in patients with active ulcerative colitis 
(UC), and ganciclovir therapy is effective in patients with 
steroid-refractory UC. This study aimed to determine the long-
term outcomes of CMV reactivation and the long-term thera-
peutic efficacy of ganciclovir treatment. Methods: This retro-
spective multicenter study included a cohort of 72 patients 
with moderate-to-severe UC who were evaluated for CMV 
reactivation at the time of their initial UC flare. Colectomy, 
disease relapse, and the recurrence rate of CMV reactivation 
were investigated. Results: The mean duration of follow-up 
for the 72 patients was 43.16±19.78 months (range, 1 to 67 
months). The cumulative colectomy (log-rank, p=0.025) and 
disease flare-up rates (log-rank, p=0.048) were significantly 
higher in the CMV-positive group. Of the 11 patients who 
were successfully treated with ganciclovir in the initial treat-
ment, three patients (27.3%) experienced CMV reactivation, 
and six patients (54.5%) experienced poor outcomes, such 
as the need for colectomy or a steroid-dependent state. Con-
clusions: The patients who had CMV-reactivated UC showed 
poor outcomes at the long-term follow-up, and the long-term 
efficacy of ganciclovir therapy was marginal. Careful assess-
ment is necessary for patients who exhibit evidence of CMV 
reactivation. (Gut Liver 2014;8:643-647)
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INTRODUCTION
Human cytomegalovirus (CMV) is a member of Herpesviridae 
family and is ubiquitous in the environment. After a primary 
asymptomatic infection, CMV has a lifelong latency.1,2 Proin-
flammatory cytokines (tumor necrosis factor-α or interferon-γ) 
can induce active CMV replication and migration to inflamed 
tissue.3,4 Patients with inflammatory bowel disease (IBD) are at a 
high risk of CMV reactivation. Two factors that are involved in 
CMV reactivation in patients with IBD are an inherent factor of 
disease severity and an iatrogenic factor of immunosuppressive 
medication.5 
Recent prospective studies have shown that CMV infection 
in patients with IBD is associated with poor outcomes.6-10 In our 
previous study,10 we reported that CMV reactivation is frequent-
ly observed in patients with moderate to severe ulcerative colitis 
(UC), especially in patients with steroid-refractory UC. Ganciclo-
vir has also been shown to be an effective treatment for steroid-
refractory UC in patients who had CMV reactivation. Although 
many clinicians have the opinion that the long-term clinical 
outcomes of IBD patients with reactivated CMV infection are 
unfavorable, there is only one report on the long-term clini-
cal outcomes of CMV infection in IBD patients.11 Moreover, the 
long-term efficacy of ganciclovir therapy in patients with UC 
has not yet been determined. Therefore, in this study, we evalu-
ated the long-term clinical outcomes of a cohort of patients 
with active UC for CMV evaluation, focusing on the cumulative 
colectomy and remission maintenance rates. 
644  Gut and Liver, Vol. 8, No. 6, November 2014
MATERIALS AND METHODS
1. Patients 
Seventy-two consecutive patients were enrolled prospectively 
between July 2007 and December 2008 from 10 referral medical 
centers in Korea in the CMV cohort.10 Initially, the incidence of 
CMV reactivation and the clinical efficacy of ganciclovir were 
evaluated in this cohort. The patients included in this cohort 
were hospitalized, with a Mayo Clinic score between 8 and 12. 
In addition, only patients with left-sided or extensive colitis 
were enrolled. The 72 patients were grouped into a CMV-pos-
itive (n=31) and CMV-negative group (n=41) according to the 
results of CMV assessment at the initial UC flare-up. The base-
line characteristic of these two groups showed no differences in 
respects with age, sex, disease duration, extent of disease, initial 
disease activity index, endoscopic grade, and previous treatment 
with azathioprine.10 Cumulative colectomy, disease relapse, and 
recurrence of CMV reactivation rates were investigated retro-
spectively from 2 months after initial flare-up to January 2013. 
The Institutional Ethics Committee of each institute approved 
the study protocol. 
2. Criteria for the diagnosis of CMV reactivation
The presence of CMV was defined as serologic detection of 
CMV IgM antibody or histologic detection of inclusion bodies 
on hematoxylin and eosin-stained sections, positive immuno-
histochemical staining, or CMV DNA amplification by poly-
merase chain reaction. Any positive results were regarded as 
evidence of CMV reactivation. 
3. Statistical analysis
Data are expressed as mean±standard deviation. Categorical 
data were compared using a chi-square test (Fisher exact test). 
The Kaplan-Meier method was used for cumulative colectomy 
and remission maintenance rates, and differences between 
CMV-positive and CMV-negative groups were analyzed using 
the log-rank test. Statistical analysis was performed using the 
SPSS package for Windows version 18.0 (SPSS Inc., Chicago, IL, 
USA). A two-tailed p-value <0.05 was considered to be statisti-
cally significant.
RESULTS 
1. Patient follow-up 
The mean duration of follow-up was 43.16±19.78 months 
(range, 1 to 67 months). Of the 72 patients, 11 (15.3%) had not 
been followed-up in January 2013, approximately a 5-year 
period. Five patients (16.1%) from the CMV-positive group 
dropped out during the follow-up period and six (14.6%) from 
the CMV-negative group dropped out (p=0.861). 
2. The cumulative colectomy rate 
In the CMV-positive group, a total of 11 patients (35.3%) 
underwent colectomy at the time of their initial flare-up (three 
patients) or during the follow-up period (eight patients). Mean-
while, four patients (9.8%) underwent colectomy in the CMV-
negative group at the time of their initial flare-up (one patient) 
or during the follow-up period (three patients). The cumulative 
colectomy rate was significantly higher in the CMV-positive 
group than in the CMV-negative group (log rank, p=0.025) (Fig. 
1).
Fig. 1. Kaplan-Meier estimation of the cumulative colectomy rates of 
the cytomegalovirus (CMV)-positive and CMV-negative groups with 
moderate-to-severe ulcerative colitis. The CMV-positive group (n=8) 
had a significantly higher colectomy rate compared with the CMV-
negative group (n=3) during long-term follow-up (log-rank, p=0.025). 
Fig. 2. Kaplan-Meier estimation of the sustained clinical remission 
rate between the cytomegalovirus (CMV)-positive and CMV-negative 
groups with moderate-to-severe ulcerative colitis. The CMV-positive 
group showed a significantly lower sustained clinical remission rate 
during the follow-up period compared with the CMV-negative group 
(p=0.048).
Kim YS, et al: Long-Term Outcome of CMV Infection in UC  645
3. The sustained clinical remission rate
After the initial flare, 28 patients in the CMV-positive group 
and 40 patients in the CMV-negative group entered clinical re-
mission. However, many patients presented with several times 
of flare-up after the initial remission and during the approxi-
mately 5-year follow-up period. Overall, the sustained clinical 
remission rate was significantly lower in the CMV-positive 
group than in the CMV-negative group (log rank, p=0.048) (Fig. 
2).
4. CMV reactivation rate 
Six patients (8.3%) showed evidence of CMV reactivation 
during the follow-up period; three were from the CMV-negative 
group (7.3%) and were treated successfully with ganciclovir 
therapy, and three were from the CMV-positive group (9.7%) 
(p=0.720). These three patients in the CMV-positive group were 
treated successfully with ganciclovir initially; however, they ex-
perienced the recurrences of CMV reactivation at the 1-year (one 
patient) and 2-year (two patients) follow-up periods. CMV reac-
tivation after successful ganciclovir therapy was not uncommon 
(27.3%). 
5. Outcomes of ganciclovir therapy
Of the 11 patients who were successfully treated with gan-
ciclovir for their initial flare-up, three patients (27.3%) experi-
enced a CMV reactivation. Despite repeated treatment with gan-
ciclovir, two patients eventually underwent colectomy owing to 
a poor response to ganciclovir. Six patients (54.5%) experienced 
another disease flares, one patient underwent colectomy, three 
patients became steroid dependent and started on infliximab, 
and two patients entered remission after steroid treatment. An-
other two patients dropped-out at the 1-year (one patient) and 
2-year (one patient) follow-ups. Therefore, among nine patients 
who were still enrolled in the study at the approximately 5-year 
follow-up, six patients (66.7%) showed a poor outcome such as 
colectomy or a steroid-dependent state (Fig. 3). Among the pa-
tients who had the evidence of CMV reactivation, but improved 
with steroid treatment at initial flare, five patients underwent 
colectomy eventually during follow-up periods.
DISCUSSION
The CMV infection rate is reported as 40% to 100% of the 
worldwide adult population.1,2 The prevalence of CMV infec-
tion appears to be higher in developing countries, as the trans-
mission of CMV is through close personal contact. In Korea, 
laboratory evidence of prior infection of CMV (CMV IgG) in the 
year 2000 was reported in 92% of the general population.12 A 
recent study of the Chinese population reported the prevalence 
of CMV IgG in Chinese IBD patients to be 76.11%.13 Therefore, 
we believe that CMV reactivation is more frequent in Asian 
IBD patients than in Western patients, and clinicians in Asian 
countries should pay more attention to CMV reactivation in IBD 
patients. 
Most cases of CMV reactivation in patients with IBD occur in 
those treated with steroids and/or immunosuppressants. Howev-
er, several studies suggested that disease severity itself plays an 
important role in CMV reactivation. Dimitroulia et al.14 reported 
that detection of the CMV genome in intestinal tissue is 20 
times more likely in UC patients than in controls. Additionally, 
the CMV genome was detected more frequently in patients with 
severe UC than mild to moderate UC. In addition, several stud-
ies identified CMV reactivation in steroid-naive UC patients,15,16 
indicating that severe inflammation of colonic mucosa triggered 
the reactivation of CMV. Our previous study also showed that 
Fig. 3. Clinical long-term outcomes 
in patients with moderate-to-severe 
ulcerative colitis who exhibited 
evidence of cytomegalovirus (CMV) 
reactivation at the time of the initial 
flare-up.
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three of 65 patients (4.5%) with newly diagnosed, moderate to 
severe UC had evidence of CMV infection,17 although they did 
not received any steroid or immunosuppressant therapy. These 
results suggest that severe colonic inflammation itself is an 
important trigger for CMV reactivation. Moreover, the natural 
course of UC in patients with CMV reactivation might be worse 
than that in CMV negative patients, because severe inflamma-
tion itself can cause a poor outcome.18 These suggestions are in 
concordance with the long-term outcomes of our study. In the 
CMV-positive group, the cumulative colectomy rate over 43.16 
months was significantly higher compared to that in the CMV-
negative group (log rank, p=0.025). In addition, the cumulative 
disease relapse rate was significantly higher in CMV-positive 
group (log rank, p=0.048). A recent study demonstrated similar 
results; their colectomy rate was significantly higher in patients 
with IBD and CMV (29%) compared with the control group of 
patients with IBD but no CMV (11.2%) (p=0.007) over a 10-year 
observation period.11 They suggested that the presence of CMV 
in patients with IBD may increase the risk of colectomy, al-
though the mechanism is not yet clear. In addition, Park et al.19 
reported that a history of CMV reactivation within 3 months 
prior to infliximab treatment acted as an independent positive 
predictor of nonresponse to infliximab. It is still unclear how 
CMV reactivation causes the refractory response to steroid or 
infliximab treatment in UC.
The European Crohn’s and Colitis Organization (ECCO) guide-
lines currently recommend the use of antiviral therapy for CMV 
infection complicating UC.20 In our previous study, we treated 
14 patients with UC who were steroid-refractory and had evi-
dence of CMV reactivation with ganciclovir, and 11 (79%) 
improved.10 These 11 patients avoided the need for colectomy 
in the short-term. However, the long-term outcome of these pa-
tients showed a marginal efficacy of antiviral therapy. Among 
the nine patients who gave clinical information at the end-point 
of the study, six (66.7%) presented with an unfavorable out-
come such as colectomy or a steroid-dependent state. These re-
sults show that despite successful treatment with ganciclovir in 
the short-term, patients with UC and reactivated CMV infection 
should be managed carefully to avoid poor long-term outcomes. 
CMV reactivation occurred in 27.3% of patients who had suc-
cessful treatment with ganciclovir. Al-Zafiri et al.11 reported that 
no significant difference in outcomes were noted with antiviral 
therapy in IBD patients with CMV. However, our data showed 
that antiviral therapy was clearly effective in the short-term 
and was effective in the long-term in half of the patients. UC 
patients with CMV reactivation tend to have severe colonic in-
flammation, and this inherent factor could affect the long-term 
clinical outcomes, such as colectomy.18 Moreover, it is clear that 
the presence of CMV is associated with the severity of colitis 
and an increased risk of colectomy.21
Our study has several limitations. First, we did not provide 
strict protocols for the long-term assessment of CMV in the 
cohort of patients with active UC. After the initial flare-up and 
CMV evaluation, the patients were followed-up at 10 participat-
ing centers. Therefore, there may have been some heterogene-
ities in observation and treatment strategies among the centers. 
However, we wanted to observe the natural course of UC pa-
tients with reactivated CMV infection. Secondly, the size of the 
patient cohort was relatively small, and 11 patients dropped-
out during the follow-up period. The drop-out rate of patients 
showed no difference between CMV-positive and CMV-negative 
groups (p=0.861). It is postulated that these 11 patients might 
have a good clinical course; they would have visited a partici-
pating center  if the patients experienced a flare-up.
In conclusion, patients with UC who experienced reactivation 
of CMV infection showed poor outcomes at long-term follow-
up. This group had a higher rate of colectomy and had more 
frequent disease flare-ups. Although the short-term efficacy of 
ganciclovir treatment was favorable, the long-term efficacy was 
marginal. Therefore, careful monitoring is necessary for patients 
with moderate to severe UC who have evidence of CMV reacti-
vation.
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